Accounting for between-study variation in incremental net benefit in value of information methodology

Health Economics (United Kingdom)

Volumn 21, Issue 10, 2012, Pages 1183-1195

  Willan, Andrew R ^a,b   Eckermann, Simon ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

between study variation; optimal trial design; value of information

Indexed keywords

ARTICLE; HEALTH CARE COST; MEDICAL RESEARCH; PRIORITY JOURNAL; SAMPLE SIZE; STATISTICAL ANALYSIS; STUDY DESIGN;

CESAREAN SECTION; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MODELS, ECONOMIC; PREGNANCY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SAMPLE SIZE; VERSION, FETAL;

EID: 84865865364     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1781     Document Type: Article

References (40)

1. Ades AE, Lu G, Claxton K,. 2004. Expected value of sample information calculations in medical decision modeling. Medical Decision Making 24: 207-227. (Pubitemid 38391940)
2. Ades AE, Lu G, Higgins JPT,. 2005. The interpretation of random-effects meta-analysis in decision models. Medical Decision Making 25: 646-654. (Pubitemid 41667133)
3. Briggs A, Nixon R, Dixon, S, Thompson S,. 2005. Parametric modelling of cost data: some simulation evidence. Health Economics 14: 421-428. (Pubitemid 40514754)
4. Chiba N, van Zanten SJ, Sinclair P, Ferguson RA, Escobedo S, Grace E,. 2002. Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial. BMJ 324: 1012-1016. (Pubitemid 34457514)
5. Claxton K,. 1999. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18: 341-364. (Pubitemid 29242816)
6. Claxton K, Posnett J,. 1996. An economic approach to clinical trial design and research priority setting. Health Economics 5: 513-524.
7. Claxton K, Thompson KM,. 2001. A dynamic programming approach to the efficient design of clinical trials. Journal of Health Economics 20: 797-822. (Pubitemid 32743392)
8. De Santis F,. 2006. Power priors and their use in clinical trials. The American Statistician 60: 122-129. (Pubitemid 43813288)
9. Eckermann S, Karnon J, Willan AR,. 2010. The value of Value of Information: best informing research design and prioritization using current methods. PharmacoEconomics 28: 699-709.
10. Eckermann S, Willan AR,. 2007. Expected value of information and decision making in HTA. Health Economics 16: 195-209. (Pubitemid 46206613)
11. Eckermann S, Willan AR,. 2008a. Time and EVSI wait for no patient. Value in Health 11: 522-526.
12. Eckermann S, Willan AR,. 2008b. The option value of delay in health technology assessment. Medical Decision Making 28: 300-305. (Pubitemid 351713293)
13. Eckermann S, Willan AR,. 2009. Globally optimal trial design for local decision making. Health Economics 18: 203-216.
14. Gittins J, Pezeshk H,. 2000a. How large should a trial be? The Statistician 49: 177-197.
15. Gittins J, Pezeshk H,. 2000b. A behavioral Bayes method for determining the size of a clinical trial. Drug Information Journal 34: 355-363. (Pubitemid 30350988)
16. Halpern J, Brown Jr BW, Hornberger J,. 2001. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Statistics in Medicine 20: 841-858. (Pubitemid 32249084)
17. Higgins JPT, Whitehead A,. 1996. Borrowing strength from external trials in a meta-analysis. Statistics in Medicine 15: 2733-2749. (Pubitemid 27011054)
18. Hornberger JC, Brown Jr BW, Halpern J,. 1995. Designing a cost-effective clinical trial. Statistics in Medicine 14: 2249-2259.
19. Hornberger J, Eghtesady P,. 1998. The cost-benefit of a randomized trial to a health care organization. Controlled Clinical Trials 19: 198-211. (Pubitemid 28191974)
20. Hutton EK, Kaufman K, Hodnett E, Amankwah K, Hewson SA, McKay D, Szalai JP, Hannah ME,. 2003. External cephalic version beginning at 34 weeks' gestation versus 37 weeks' gestation: a randomized multicenter trial. American Journal of Obstetrics and Gynecology 189: 245-254. (Pubitemid 36886558)
21. Ibrahim JG, Chen MH,. 2000. Power prior distributions for regression models. Statistical Science 15: 46-60.
22. Kikuchi T, Pezeshk H, Gittins J,. 2008. A Bayesian cost-benefit approach to the determination of sample size in clinical trials. Statistics in Medicine 27: 68-82. (Pubitemid 351193660)
23. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR,. 2005. How vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Statistics in Medicine 24: 2401-2428. (Pubitemid 41093922)
24. Morris C,. 1983. Parametric empirical Bayes inference: theory and applications. Journal of the American Statistical Association 78: 47-55.
25. Pezeshk H, Gittins J,. 2002. A fully Bayesian approach to calculating sample sizes for clinical trials with binary response. Drug Information Journal 36: 143-150. (Pubitemid 34208210)
26. Pezeshk H,. 2003. Bayesian techniques for sample size determination in clinical trials: a short review. Statistical Methods in Medical Research 12: 489-504. (Pubitemid 37461098)
27. Pinto EM, Willan AR, O'Brien BJ,. 2005. Cost-effectiveness analysis for multinational clinical trials. Statistics in Medicine 24: 1965-1982. (Pubitemid 40895553)
28. Smith TC,. 1995. Interpreting evidence from multiple randomised and non-randomised studies. PhD thesis. University of Cambridge.
29. Smith TC, Spiegelhalter DJ, Thomas A,. 1995. Bayesian approaches to random-effects metaanalysis: a comparative study. Statistics in Medicine 14: 2685-2699. (Pubitemid 26014258)
30. Spiegelhalter DJ, Abrams KR, Myles JP,. 2004. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley: Chichester UK.
31. Sutton AJ, Abrams KR,. 2001. Bayesian methods in meta-analysis and evidence synthesis. Statistical Methods in Medical Research 10: 277-303. (Pubitemid 32691157)
32. Welton NJ, Ades AE, Caldwell DM, Peters TJ,. 2008. Research prioritization based on expected value of partial perfect information: a case-study on interventions to increase uptake of breast cancer screening (with discussion). Journal of the Royal Statistical Association, Series A 171: 807-841.
33. Willan AR,. 2004. Incremental net benefit in the analysis of economic data from clinical trials with application to the CADET-Hp Trial. European Journal of Gastroenterology and Hepatology 16: 543-549. (Pubitemid 38703862)
34. Willan AR,. 2007. Clinical decision making and the expected value of information. Clinical Trials 4: 279-285. (Pubitemid 47400539)
35. Willan AR,. 2008. Optimal sample size determinations from an industry perspective based on the expected value of information. Clinical Trials 5: 587-594.
36. Willan AR, Briggs AH,. 2006. The Statistical Analysis of Cost-effectiveness Data. Wiley: Chichester.
37. Willan AR, Pinto EM, O'Brien BJ, Kaul P, Goeree R, Lynd L, Armstrong PW,. 2005. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. Health Economics 14: 327-338. (Pubitemid 40514747)
38. Willan AR, Kowgier ME,. 2008. Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods. Clinical Trials 5: 289-300.
39. Willan AR, Pinto EM,. 2005. The expected value of information and optimal clinical trial design. Statistics in Medicine 24: 1791-1806 (Correction. Statistics in Medicine 25: 720.). (Pubitemid 40872643)
40. Willan AR, Eckermann S,. 2010. Optimal clinical trial design using value of information methods with imperfect implementation. Health Economics 19: 549-561.